Cadherin 6 (CDH6) is a transmembrane protein with high expression during embryonic kidney development, with very limited expression in adult tissues but overexpressed in several malignancies such as ovarian or renal cancer, and it is tied disease progression and poor prognosis. This pattern of expression makes it an attractive target for antibody-drug conjugate (ADC) development.
Claudin 18.2 (CLDN18.2) is involved in the formation of tight junctions and is expressed in normal gastric mucosa, maintaining its expression during malignant transformation of the gastric epithelium. It is also aberrantly expressed in other tumor types, such as esophageal, pancreatic and lung adenocarcinoma, making it an attractive target for cancer immunotherapy.
Researchers from Arvinas Inc. and affiliated organizations presented the discovery and preclinical evaluation of ARV-766, a novel androgen receptor (AR) degrading proteolysis targeting chimera (PROTAC), being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Tumor-associated calcium signal transducer 2 (TROP2), a clinically validated target in oncology, is a glycoprotein overexpressed in several solid tumors such as breast, lung, pancreatic, ovarian and prostate cancer. TROP2 antibody-drug conjugates (ADCs) have shown significant efficacy in a large number of cancer types but still are linked to substantial safety issues.
Researchers at 1200 Pharma LLC have undertaken preclinical analysis of KRAS G12C inhibitors in clinical phases with the aim of finding an explanation for the differences observed in therapeutic efficacy in tumor sites other than lung, including lung-derived metastases. Results pointed to potency and pharmacokinetics as key drivers of efficacy.
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is an inhibitory factor on natural killer (NK) and T cells and is expressed in several cancer types and immune cells such as macrophages and neutrophils. Researchers from Suzhou Neologics Bioscience Co. Ltd. have investigated CEACAM1 as a potential target for cancer immunotherapy.
RSS
